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Introduction: The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions
over 3 weeks in 4000 patients. We discuss concerns raised by the radiotherapy community in relation to implementing this schedule.
Ipsilateral Breast Tumour Relapse (IBTR): Published estimated 5-year IBTR with 95% CI after 40 Gy in 15 fractions was 2.1% (95% CI 1.4e3.1), 1.7% (1.2e1.6) after
27 Gy and 1.4% (0.2e2.2) after 26 Gy, emphatically showing non-inferiority of the 5-fraction regimens. Subgroup analyses comparing IBTR in 26 Gy versus 40 Gy
show no evidence of differential effect regarding age, grade, pathological tumour size, nodal status, tumour bed boost, adjuvant chemotherapy, HER2 status and
triple negative status. The number of events in these analyses is small and results should be interpreted with caution. There was only 1 IBTR event post-
mastectomy.
Normal tissue effects: The 26 Gy schedule, on the basis of similar NTE to 40 Gy in 15 fractions, is the recommended regimen for clinical implementation. There is
a low absolute rate of moderate/marked NTE, these are predominantly moderate not severe change. Subgroup analyses comparing clinician-assessed moderate
or marked adverse effect for 26 Gy versus 40 Gy show no evidence of differential effects according to age, breast size, surgical deficit, tumour bed boost, or
adjuvant chemotherapy.
Radiobiological considerations: The design of the FAST-Forward trial does not control for time-related effects, and the ability to interpret clinical outcomes in
terms of underlying biology is limited. There could conceivably be a time-effect for tumour control. A slight reduction in a/b estimate for the late normal tissue
effects of test regimens might be a chance effect, but if real could reflect fewer consequential late effects due to lower rates of moist desquamation.
Conclusion: The 26 Gy 5-fraction daily regimen for breast radiotherapy can be implemented now.
 2021 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
Key words: Breast cancer; hypofractionation; non-inferiority RCT; radiobiology; radiotherapy; tumour controlIntroduction
Over the last 30 years, breast radiotherapy fractionation
has been systematically investigated and debated. Moder-
ate hypofractionation, using 15 or 16 fractions over 3 weeks
delivering total doses in the range 40e42.5 Gy, has become
the widespread international standard [1e3]. Recent pub-
lished studies of five-fraction breast radiotherapy describe
safe, effective and simpler regimens that will probablyAuthor for correspondence: A.M. Brunt, David Weatherall Building,
School of Medicine, University of Keele, Keele, Staffordshire ST5 5BG, UK.
E-mail address: m.brunt@keele.ac.uk (A.M. Brunt).
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FAST-Forward trial [4] reported outcomes, in relation to
both tumour control and normal tissue effects (NTE), for 26
and 27 Gy in five fractions over 1 week versus 40 Gy in 15
fractions over 3 weeks in more than 4000 patients. Selec-
tion of total doses for the five-fraction schedules was
informed by earlier trials, including the FAST trial of 915
patients testing 28.5 and 30 Gy in five fractions delivered
once weekly versus 50 Gy in 25 fractions over 5 weeks,
which has now published 10-year results [5].
At a consensus meeting held in October 2020 under the
auspices of The Royal College of Radiologists, the UK breast
cancer radiotherapy community voted for five-fraction breastCollege of Radiologists. This is an open access article under the CC BY license
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therapy (https://www.rcr.ac.uk/publication/postoperative-
radiotherapy-breast-cancer-hypofractionation-rcr-consensus-
statements). However, some commentators suggest caution in
adopting the schedule now. In the Editorial accompanying the
FAST-Forward results, Levyand Rivera [6] agree that results are
practice-changing for low-risk patients, but want longer-term
disease outcomes and clinically defined subgroup analyses.
Offersen et al. [7] argued that 26Gy infive fractions is expected
to be less effective than 40 Gy in 15 fractions based on con-
ventionala/bestimates.Weexplore these issues, togetherwith
recurring themes that have come upwhenpresenting the data
since publication.Ipsilateral Breast Tumour Relapse
FAST-Forward is a non-inferiority trial with ipsilateral
breast tumour relapse (IBTR) as the primary end point.
Based on START trial data [8,9] and incorporating subse-
quent improvements in surgical technique and systemic
therapy, it was anticipated that the incidence of IBTR by 5
years in the FAST-Forward control group giving 40 Gy in 15
fractions would be 2%. Following discussions with clinicians
and patient advocates, a non-inferiority margin of 1.6% was
prespecified in the protocol, which required a sample size of
4000 patients. The estimated 5-year incidence of IBTR after
40 Gy in 15 fractions was 2.1% (95% confidence interval
1.4e3.1), 1.7% (1.2e1.6) after 27 Gy and 1.4% (0.2e2.2) after
26 Gy. These upper confidence limits excluded an increase
in IBTR of >1.6% after both five-fraction schedules, with P ¼
0.0022 and P ¼ 0.00019 for non-inferiority of 27 and 26 Gy
schedules, respectively, compared with 40 Gy in 15
fractions.
These results on IBTR are definitive. However, one
requirement proposed by commentators is longer follow-
up, as IBTR continues beyond 5 years. Other trials of hypo-
fractionation have reported almost identical hazard ratios
for IBTR at 5 and 10 years, the relevant metrics for com-
parisons of effect. For example, START-B [10] incidence rates
of IBTR at 5/10 years after 40 Gy in 15 fractions versus 50 Gy
in 25 fractions were 1.9%/3.8% versus 3.3%/5.2%, respec-
tively, reflecting crude hazard ratios of 0.72 (95% confidence
interval 0.43e1.21) and 0.70 (95% confidence interval
0.46e1.07), i.e. unchanged between 5 and 10 years. The
Ontario Clinical Oncology Group [11] reported IBTR rates at
5/10 years after 50 Gy in 25 fractions versus 42.5 Gy in 16
fractions of 3.2%/6.7% and 2.8%/6.2%, respectively, giving an
absolute difference of 0.4% (95% confidence interval
e1.5e2.4%) and 0.5% (95% confidence intervale2.5e3.5%) at
5- and 10-year timepoints.
Commentators refer to subgroups for whom hypo-
fractionation may not be so effective, but the empirical data
are reassuring. The 2011 American Society for Radiation
Oncology evidence-based guidelines [12] were unable to
confirm agreement on hypofractionation in patients <50
years. The small number of patients included in trials and anPlease cite this article as: Brunt AM et al., Five-fraction Radiotherapy for
https://doi.org/10.1016/j.clon.2021.04.016increased risk of IBTR at a young age were cited, but no
evidence of an adverse outcome by age after hypofractio-
nation has been reported. A post-hoc analysis of tumour
grade in the Ontario Clinical Oncology Group trial [11]
suggested an interaction of grade and randomisation group,
but subsequent central analysis of tumour blocks reported
no trend for patients with high-grade tumours to be
disadvantaged after 42.5 Gy in 16 fractions [13]. They also
found that tumour grade and molecular subtype did not
predict response to hypofractionation. A subgroup meta-
analysis of locoregional relapse was carried out of the
START-P [14], -A [8] and -B [9] trials in 5861 patients
reporting 10-year results [10]. Treatment effects of hypo-
fractionation in terms of tumour control were not signifi-
cantly different from 50 Gy in 25 fractions when examined
by age, type of primary surgery, axillary node status, tumour
grade, use of adjuvant chemotherapy or boost radiotherapy.
The 2018 American Society for Radiation Oncology
evidence-based guidelines approved hypofractionated
breast radiotherapy with 40/42.5 Gy in 15/16 fractions over
3 weeks, irrespective of age, tumour grade or receptor sta-
tus [1].
Wang et al. [15] reported on 810 patients in a single
institution randomised non-inferiority trial of hypofractio-
nated radiotherapy post-mastectomy. All patients under-
went axillary dissection andwere at least four-node positive
or T3e4, unless they received neoadjuvant chemotherapy, in
which case either clinical stage III or pathological axillary
node-positive patients were eligible. The hypofractionated
schedule was 43.5 Gy in 15 fractions over 3 weeks versus 50
Gy in 25 fractions over 5 weeks as standard. The radio-
therapy target volume included the chest wall, level 3 axilla
and supraclavicular fossa. The 5-year locoregional recur-
rence rate was 8.3% (90% confidence interval 5.8e10.7) with
the 15-fraction schedule and 8.1% (90% confidence interval
5.4e10.6) with the 25-fraction schedule. With a P < 0.0001
for non-inferiority they concluded that the hypofractionated
regimen was non-inferior to standard.
FAST-Forward reported non-inferior IBTR for both five-
fraction schedules and given the preceding arguments we
would not expect inferiority to be observed in any sub-
groups, but what did we find? In total, 1545 (37.8%) patients
were in the high-risk category as defined by age <50 years,
grade 3 tumour or both, and this was a stratification factor
at randomisation. Retrospective subgroup analyses
comparing IBTR in 26 Gy versus 40 Gy provided no evidence
of a differential effect according to age, grade, pathological
tumour size, nodal status, tumour bed boost, adjuvant
chemotherapy, HER2 status and in triple-negative patients
(Figure 1). Confidence intervals for the hazard ratios over-
lapped for the subgroups, although the number of events in
these analyses was small (52); hence, results should be
interpreted with caution, as the statistical power was low.
Subgroup analysis according to type of primary surgery was
not possible as there was only one IBTR event post-
mastectomy in a control group patient (out of 91) and
none in the 173 patients treated with five fractions. Table 1Breast Cancer: FAST-Forward to Implementation, Clinical Oncology,
Fig 1. Subgroup analyses of time to ipsilateral breast tumour relapse for (a) 26 Gy in five fractions versus 40 Gy in 15 fractions and (b) 27 Gy in
five fractions versus 40 Gy in 15 fractions.
A.M. Brunt et al. / Clinical Oncology xxx (xxxx) xxx 3shows the frequencies and number of patients in each
category of age<50 years, grade 3, post-mastectomy, triple-
negative and HER2-positive tumours. No evidence to signal
concern was seen for the five-fraction schedules. The use ofPlease cite this article as: Brunt AM et al., Five-fraction Radiotherapy for
https://doi.org/10.1016/j.clon.2021.04.016boost and dose/fractionation, both declared prior to ran-
domisation, was balanced between the three treatment
groups, minimising the risk of bias in dose intensity be-
tween trial groups.Breast Cancer: FAST-Forward to Implementation, Clinical Oncology,
Table 1
Ipsilateral breast tumour relapse by higher risk subgroup in FAST-Forward
Subgroup Event/number 40 Gy/15 fractions 27 Gy/5 fractions 26 Gy/5 fractions
Age under 50 years at randomisation Events 3 7 4
Number at risk 198 189 217
Grade 3 Events 20 15 8
Number at risk 386 389 378
Mastectomy Events 1 0 0
Number at risk 91 89 84
ER-negative/HER2-negative* Events 10 5 3
Number at risk 111 96 128
HER2-positive Events 4 7 2
Number at risk 135 137 135
* PR status was not mandatory in the UK or the trial but when ER/HER2 were negative PR status was negative/positive/unknown in 265/
18/52, respectively.
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In FAST-Forward, late NTE assessed by clinicians, patients
and photographs were key secondary end points. The 26 Gy
in five daily fractions schedule, on the basis of similar NTE to
40 Gy in 15 fractions, is the recommended regimen for
clinical implementation. By ‘similar’ we mean that NTE
were neither statistically nor clinically significantly
different from 40 Gy in 15 fractions with respect to clini-
cian- or patient-assessed outcomes, including photographic
assessments conducted blind to treatment allocation. The
27 Gy five-fraction schedule was statistically significantly
different to the 40 Gy standard for many late NTE and also to
the 26 Gy schedule, confirming the sensitivity of trial
outcome measures to detect a difference in dose intensity
corresponding to 3 Gy in 2 Gy equivalents assuming a/b ¼ 2
Gy (see below). The 27 Gy five-fraction regimen exhibited
late NTE rates of comparable magnitude to 50 Gy in 25 daily
fractions. To provide some perspective for the late NTE after
five-fraction regimens, 40 Gy in 15 fractions is equivalent to
about 46 Gy in 2 Gy fractions in terms of late NTE compared
with 50 Gy in 25 fractions according to START trial out-
comes [11]. In FAST-Forward, the 26 Gy regimen is compa-
rable to 47 Gy in 2 Gy equivalents in terms of late NTE.
Early NTE are much less responsive to fraction size than
late NTE, the contribution of total dose being relativelyTable 2
Breast clinician and patient assessment in FAST-Forward
Normal tissue effect Clinician or
patient assessed
Moderate or marke
events in 40 Gy at 5
years (%)
Breast distortion Clinician 32/916 (3.5)




Breast appearance changed Patient 140/432 (32.4)
Breast smaller Patient 122/428 (28.5)
Breast harder or firmer Patient 61/428 (14.2)
* Clinician assessment is longitudinal all years. Patient assessment is l
y Statistical significance defined in the statistical analysis plan for no
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in that breast erythema was less intense and also settled a
fortnight earlier after five-fraction than 15-fraction sched-
ules [17]. In this context, the milder erythema was a
response to 26 and 27 Gy total dose levels much more than
to fraction sizes of 5.2 and 5.4 Gy. Acute reactions were also
milder in both five-fraction arms (total doses 28.5 and 30
Gy) of the FAST trial than the 50 Gy schedule [18].
Induration is a key late NTE that is expected to increase
with the passage of time, irrespective of radiation schedule.
Other factors contributing to breast appearance include fat
necrosis and oedema, particularly in the early years [19].
Table 2 shows FAST-Forward breast assessments recorded
separately by patients and clinicians. It is important to
consider the absolute frequencies of events as well as the
relative comparisons between schedules. For example, for
breast shrinkage, the most frequent of the clinician-
assessed effects, the prevalence of moderate or marked ef-
fects at 5 years was 5.5% in 40 Gy and 6.8% in 26 Gy, and the
5-year prevalence of moderate or marked induration
outside the tumour bed was only 0.1% and 2.1% in 40 and 26
Gy, respectively. For all clinician-assessed events docu-
mented in the moderate/marked change categories, most
were moderate rather than marked in severity.
With regards to increasing frequency of late NTE with
time, stability of the hazard ratio at longer timepoints isd Moderate or marked
events in 26 Gy at 5
years (%)
Odds ratio comparison





53/955 (5.5) 1.20 (0.91e1.60) 0.19
65/954 (6.8) 1.05 (0.82e1.33) 0.71
20/955 (2.1) 1.90 (1.15e3.14) 0.013
136/429 (31.7) 0.91 (0.75e1.10) 0.33
103/429 (24.0) 0.81 (0.65e1.00) 0.053
74/425 (17.4) 1.22 (1.00e1.48) 0.048
ongitudinal 3 months to 5 years, adjusting for baseline assessment.
rmal tissue end points as P < 0.005 to allow for multiple testing.
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in Table 3. The principle of the relative difference between
test and control group changing little with time can there-
fore be applied to FAST-Forward, again noting the low ab-
solute levels of marked and moderate events.
The Danish-led HYPO trial of 1864 patients tested the
non-inferiority of 40 Gy in 15 fractions in terms of breast
induration at 3 years compared with 50 Gy in 25 fractions
[7]. This important study reproduced the START-B results
with 3-year rates of induration of 11.8% (95% confidence
interval 9.7e14.1%) in the 50 Gy group and 9.0% (95% con-
fidence interval 7.2e11.1%) in the 40 Gy group (risk differ-
ence 22.7%; 95% confidence interval 25.6e0.2%; P ¼ 0.07).
Low uptake of hypofractioned whole-breast radiotherapy in
the USA, due in part to concerns of safety for patients
receiving a tumour bed boost, chemotherapy or having
large breast size, led to a randomised non-inferiority trial
[20]. The standard treatment of 50 Gy in 25 daily fractions
with a 10e14 Gy boost in five to seven fractions was tested
against 42.56 Gy in 16 daily fractions with a 10e12.5 Gy
boost in four to five fractions. In total, 106 (36.9%) of the 287
patients were defined as large breast size, with a bra cup
size of at least D. Adverse patient-reported cosmetic
outcome, the primary end point, was 5.4% lower (8.2%
versus 13.6%, P ¼ 0.002 for non-inferiority) in the hypo-
fractionated arm overall and 18.6% lower (90% upper con-
fidence limit 8% lower) for large breasted patients. They
concluded that this offers strong reassurance for hypo-
fractionation not compromising cosmetic outcome based
on large breast size.
Tsang et al. [21] looked at dose heterogeneity with
regards to the FAST trial and the risk of ‘triple trouble’. In
total, 390 full computed tomography planning data sets
were reviewed for patients where there was a baseline and
a 2-year photographic assessment, the primary end point of
FAST. The two five-fraction groups were combined for
analysis and there was no significant difference between
these and the control for breast volume or for patient
tumour and treatment characteristics from the whole FAST
population. Multiple logistic regression analyses showed
that after adjusting for breast size (and surgical deficit),
there was no evidence of late NTE associated with dose
inhomogeneity using various definitions of hotspots. The
effect of inhomogeneity was not significantly different for
any of the dosimetric parameters between control and five-
fraction schedules. In FAST-Forward, the a/b estimate for
any clinician-assessed moderate or marked NTE was barely
different unadjusted or when adjusted for breast size, usingTable 3
Treatment comparisons for moderate or marked breast shrinkage at 5
Trial Risk rati
START-B:
40 Gy/15 fractions versus 50 Gy/25 fractions 0.77 (0.5
FAST:
30 Gy/5 fractions versus 50 Gy/25 fractions 2.03 (1.1
28.5 Gy/5 fractions versus 50 Gy/25 fractions 1.20 (0.6
Please cite this article as: Brunt AM et al., Five-fraction Radiotherapy for
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breast size. The same lack of change was found with
photographic assessment and breast size. We can conclude
that breast size is an established factor for increased NTE
following breast radiotherapy but that hypofractionation,
including five-fraction schedules, is not an additional
concern for larger breasted patients.
In FAST-Forward, retrospective subgroup analyses
comparing the time to first clinician-assessed moderate or
marked adverse effect in the breast or chest wall for 26 Gy
versus 40 Gy provided no evidence of a differential effect of
the five-fraction schedule according to age, breast size,
surgical deficit, tumour bed boost or adjuvant chemo-
therapy, as confidence intervals for subgroups overlapped,
although the power for these retrospective subgroup ana-
lyses was low (Figure 2).
What about other organs at risk? The heart is often
mentioned, particularly as a very long follow-up is required
to assess the full risk, although there is no specific reason to
expect an increased cardiac sensitivity to hypofractionation.
Darby et al. [22] have shown that there is no safe dose to the
heart and therefore the effort is to reduce or eliminate
cardiac dose. At this early stage, after imaging and further
investigation, excluding cases confirmed not to be
radiotherapy-related, for left-sided radiotherapy therewere
six cases of ischaemic heart disease in the 40 Gy group and
three cases in the 26 Gy group. The most frequent specialist
referral we have seen is to lymphoedema clinics for breast
lymphoedema: 90 patients (6.6%) following 40 Gy, 122
(8.9%) after 27 Gy and 106 (7.7%) after 26 Gy. Breast oedema
is predominantly an early side-effect, which we have seen
settling, such that at 5 years the moderate/marked inci-
dence on clinician assessment was seven (0.7%) patients
after 40 Gy, 18 (1.8%) after 27 Gy and 17 (1.7%) patients after
26 Gy, with no oedema in 94, 92 and 93%, respectively.
These rates are low and not clinically or statistically signif-
icantly different.
Some Radiobiological Considerations: Tumours
In a review of the linear-quadratic model and implica-
tions for practice, Brand and Yarnold [23] present FAST-
Forward as an example of a trial evaluating five-fraction
hypofractionated accelerated radiotherapy. To make sense
of FAST-Forward in terms of fraction size effects, the START
trials offer a good entry point. The START-P/-A trials
[8,10,14] (1986e2003) each compared 50 Gy in 25 fractions
over 5 weeks (control) with two test dose levels of a 13-and 10 years of follow-up in previous breast radiotherapy trials




Breast Cancer: FAST-Forward to Implementation, Clinical Oncology,
Fig 2. Subgroup analyses of time to first moderate or marked clinician-assessed adverse event in breast/chest wall for (a) 26 Gy in five fractions
versus 40 Gy in 15 fractions and (b) 27 Gy in five fractions versus 40 Gy in 15 fractions.
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By controlling for time-related effects and assuming com-
plete repair of sublethal damage between fractions in all
groups, an unconfounded estimate of sensitivity to fraction
size (a/b) is possible. This simply involves identifying the
total dose in 13 fractions matching the IBTR rate in the 25-
fraction group, sometimes involving interpolation between
test dose levels. In START-A, IBTR after 13 fractions of 3.2 Gy
was closer than 13 fractions of 3.0 Gy to IBTR after 25
fractions of 2.0 Gy, from which a direct a/b estimate of 3.5
Gy (95% confidence interval 1.2e5.7) was based on the 10-
year total of 349 IBTR events in 3646 women [24]. The 8.4
Gy reduction from 50 Gy to 41.6 Gy needed to match the
IBTR of 3.2 Gy fractions with 25 fractions of 2.0 Gy is a vivid
measure of fraction size sensitivity at play.
To our knowledge, START-P/-A trials generated the only
direct clinical estimate of a/b for a cancer, others being
based on non-randomised or randomised comparisons that
do not control for one or more variables, especially time.
START-B is a good example of the latter, testing 50 Gy in 25
fractions over 5weeks against 40 Gy in 15 fractions of 2.7 Gy
over 3 weeks. Applying the a/b ¼ 3.5 generated by START-
P/-A, the equivalent total dose in 2.0 Gy fractions (EQD2/
3.5) of the 3-week schedule is only 45 Gy (Table 4), yet based
on 95 IBTR events in 2215 patients (4.3%), the test schedule
was non-inferior to 50 Gy (hazard ratio 0.77; 95% confi-
dence interval 0.51e1.16, P ¼ 0.21). In fact, the point esti-
mate 10-year IBTR rate of the 3-week regimenwas 1% lower
than the 5-week control regimen (ns). A post-hoc analysis
asked the question ‘If this difference is real, what would it
tell us about the impact of treatment time?’ [24]. We know
that in laryngeal carcinomas, at least 0.5 Gy/day can be
‘wasted’ compensating for accelerated repopulation from
the fourth week of treatment onwards, first described by
Withers et al. [25] in patients treated with primary radio-
therapy and confirmed by Lyhne et al. [26] in a randomised
clinical trial comparing 60 Gy in 30 fractions delivered five
versus six times per week. Breast cancers have relatively
low mitotic rates at presentation, but they might be in an
accelerated phase of repopulation by the time radiotherapy
starts several weeks ormonths after primary surgery and/orTable 4
2 Gy equivalents (EQD2) for regimens (referenced) with relevant a/b p
a/b Gy / Regimen/reference Y 3.7 3.5 3.0
50 Gy/25 fractions 50.0 50.0 50.0
43.5 Gy/15 fractions [16] 50.4 50.6 51.3
42.9 Gy/13 fractions [15] 52.7 53.0 54.0
42.5 Gy/16 fractions [12] 47.4 47.6 48.1
41.6 Gy/13 fractions [9] 50.4 50.7 51.6
40 Gy/15 fractions [4,8,10] 44.7 44.9 45.4
39 Gy/13 fractions [9,15] 45.9 46.1 46.8
30 Gy/5 fractions [5] 51.1 51.8 54.0
28.5 Gy/5 fractions [5] 47.0 47.7 49.6
27 Gy/5 fractions [4] 43.1 43.7 45.4
26 Gy/5 fractions [4] 40.6 41.1 42.6
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post-hoc analysis (hypothesis generating) estimated 0.6 Gy/
day (95% confidence interval 0.1e1.8, P¼ 0.02) ‘wasted’ dose
in control group patients during weeks 4 and 5 is true, it
implies about 14 0.6¼ 8 Gy of the control regimen (50 Gy)
is ‘wasted’. This implies a time-corrected EQD2/3.5 of 42 Gy
for the 5-week regimen compared with 45 Gy for the 3-
week schedule. The Danish-led HYPO trial [7] offers an in-
dependent test of START-B in a comparable group of pa-
tients, in whom the 9-year risk of locoregional recurrence
was 3.3% (95% confidence interval 2.0e5.0) in the 50 Gy in
25 fractions group compared with 3.0% (95% confidence
interval 1.9e4.5) in the 40 Gy in 15 fractions group (risk
difference 20.3%; 95% confidence interval 22.3e1.7), a result
very similar to START-B.
What havewe seen in FAST-Forward? The trial generated
an a/b estimate for IBTR of 3.7 Gy (95% confidence interval
0.3e7.1), the wide confidence interval reflecting very low
incidence of IBTR. The analysis plan did not incorporate a
hypothetical time correction, so the a/b estimate of 3.7 Gy
necessarily incorporates all underlying biology, including
fraction size sensitivity, completeness of repair and putative
time effects. Regardless of whether or not there is a time
effect, the clinically effective EQD2/3.7 of 26 Gy in five frac-
tions is 41 Gy in 2 Gy fractions (see Table 4). The difference
in estimated anti-tumour effect between this EQD2/3.7 ¼ 41
for the five-fraction schedule and EQD2/3.7 ¼ 45 Gy of 40 Gy
in 15 fractions would be too small to detect at such high
levels of local control. Nevertheless, a robust clinical
conclusion can be drawn, namely that the five-fraction
regimen has shown non-inferiority in relation to the pre-
defined 1.6% excess IBTR boundary set in the protocol.
Questions have been raised whether 26 Gy in five fractions
has any anti-tumour effect at all [27]. With a 5-year inci-
dence of IBTR of 2.1% (95% confidence interval 1.4e3.1) after
40 Gy in 15 fractions, the incidence without any radio-
therapy would be expected to be about 6% at 5 years and
10% at 10 years, according to systematic overviews of
radiotherapy effects [28]. The observed 5-year incidence of
IBTR after 26 Gy in five fractions is hardly consistent with an
absence of effect.oint values from manuscript text
2.8 2.3 2.0 1.8 1.7
50.0 50.0 50.0 50.0 50.0
51.7 52.6 53.3 53.8 54.1
54.5 55.9 56.8 57.6 58.0
48.3 49.0 49.5 49.9 50.1
52.0 53.2 54.1 54.7 55.1
45.6 46.2 46.7 47.0 47.2
47.1 48.1 48.7 49.3 49.5
55.0 57.9 60.0 61.6 62.4
50.5 53.0 54.9 56.3 57.0
46.1 48.4 50.0 51.2 51.8
43.3 45.3 46.8 47.9 48.5
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Tissues
The discussion of tumour responses above has a lot to say
about the potential impact of time on IBTR. Turning to late
NTE, meticulous data generated in human skin are consis-
tent with aminimal measurable effect of time. Turesson and
Thames [29] reported a tiny time effect for telangiectasia
associated with a complete absence of mitotic figures in
capillary endothelium on serial skin biopsies over many
weeks of radiotherapy, the lack of mitoses excluding repo-
pulation as a mechanism. The effect was thought to prob-
ably represent a very slow component of repair decaying
with a T1/2 of around 40 days. The same post-hoc investi-
gation of a time effect in breast cancer in START-B described
above included analysing the effect of time on late NTE as a
negative control, yielding an estimate of 0.14 Gy/day (95%
confidence interval e0.09 to 0.34 Gy/day, P ¼ 0.29) for a
change in photographic breast appearance [26].
The reason for providing this level of detail is that the
selection of FAST-Forward test dose levels 27 and 26 Gy
assumed, firstly, no clinically significant time effect for late
NTE between 1 and 3 weeks; secondly, complete sublethal
damage repair between fractions; and thirdly, an a/b of 2.8
Gy for late NTE, the last assumption based on the combined
estimates of a/b in START-A and FAST. On this basis, the
EQD2/2.8 of all FAST-Forward schedules relative to 50 Gy in
25 fractions are shown in Table 5, where negative values
indicate estimated NTE rates lower than 50 Gy in 25
fractions.
Although the 27 Gy test dose level was predicted to be
iso-effective for NTE with 40 Gy in 15 fractions, the
observed iso-effect for NTE at 5 years was closer to 26 Gy,
suggesting a slightly lower a/b value (see Table 4). The a/b
point estimates are all around 2 Gy, corresponding to EQD2/
2 of about 47 Gy for 26 Gy in five fractions. This compares to
EQD2/2.8 of about 46 Gy for 40 Gy in 15 fractions, the latter
using the combined estimate of a/b ¼ 2.8 for this regimen
based on START-A and FAST.Table 5
Relative EQD in 2 Gy fractions of FAST-Forward schedules and the
absolute percentage difference in adverse events (DAE) expected
compared with 50 Gy in 25 fractions assuming (i) a/b ¼ 2.8 Gy as
per START-A and FAST, (ii) complete repair of sublethal damage
between fractions and (iii) a doseeresponse gradient correspond-
ing to g¼ 1.4 as per START-A trial (https://www.icr.ac.uk/our-
research/centres-and-collaborations/centres-at-the-icr/clinical-
trials-and-statistics-unit/clinical-trials/fast_forward_page/)
Fractionation regimen EQD2/2.8 (Gy) DAE (%)*
50 Gy/25 fractions/5 weeks 50.0 reference
40.05 Gy/15 fractions/3 weeks 45.6 e12.3
27 Gy/5 fractions/1 week
(5.4 Gy/fraction)
46.1 e11.1
26 Gy/5 fractions/1 week
(5.2 Gy/fraction)
43.3 e18.8
* Negative values indicate estimated normal tissue effect rates
lower than after 50 Gy in 25 fractions.
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NTE scored in the FAST-Forward trial fall within the confi-
dence intervals ofa/bestimates forall lateNTE in the FASTand
START-P/-A trials. One interpretation, and statistically
speaking the likeliest, is that they are all internally consistent
with eachother. Alternatively, thedifferences ina/b estimates
is real, and lateNTE are truly slightlymore likelyafter 26Gy in
five fractions. If so, we exclude repopulation for the reasons
described above, leaving slow (>24 h) repair between daily
fractions reportedbyTuressonandThames[29]andmodelled
in the FAST-Forward trial protocol (appendix 2) as the likely
explanation [4]. Alternatively, lower rates of moist desqua-
mation (high a/b) after five-fraction regimens may cause less
consequential late NTE (same high a/b), enough to reduce the
a/b estimate of late NTE compared with conventional frac-
tionation. These somewhat esoteric considerations should
notobscure the all-important clinical conclusion that 26Gy in
five daily fractions offers patients comparable NTE rates and
non-inferior IBTR to 40 Gy in 15 fractions.UK Consensus and Recommendations for
Implementation
The UK consensus meeting [2] included an in-depth re-
view of the FAST-Forward results, including many of the
clinical aspects examined here. The results of FAST-Forward
were planned to be taken together with those of IMPORT
LOW [30], which had the same control regimen of 40 Gy in
15 fractions to the whole breast and, therefore, are appli-
cable to partial-breast radiotherapy. There is no clinical
rationale for excluding groups that were under-represented
unless there is a logical argument for doing so. The de-
cisions taken at the consensus meeting were to adopt 26 Gy
in five daily fractions of 5.2 Gy for whole-breast, partial-
breast and chest wall radiotherapy as the standard regimen.
The coronavirus pandemic has unexpectedly given cli-
nicians and centres all over theworld experience of 26 Gy in
five daily fractions. Audit of that experience by centre, re-
gion or country should aid confidence in incorporating it
into national or international guidelines. The original pub-
lication [4] and appendices include links to the trial protocol
as a resource; the UK consensus weblink in this document is
also a resource and the FAST-Forward team have provided
advice both to individual centres and via webinars to in-
ternational groups over the last year. The START trials’ [8,9]
5-year outcomes were published in 2008 and the 40 Gy in
15 fractions schedule was adopted as UK standard of care in
2009 (https://www.nice.org.uk/guidance/ng101) as a result,
albeit that the 10-year outcomes [10] gave clinicians and
patients confidence that the regimen was safe and effective
in the longer term. Similarly, the 26 Gy five-fraction
schedule is ready for adoption globally, and indeed is
already going through that process in some countries.
Although, based on the START [10] and FAST [5] data, it is
anticipated that outcomes will remain non-inferior at 10
years, it is important to continue collecting data to the 10-
year timepoint to provide reassurance around the longer-
term safety and efficacy of the five daily fraction schedule.Breast Cancer: FAST-Forward to Implementation, Clinical Oncology,
A.M. Brunt et al. / Clinical Oncology xxx (xxxx) xxx 9Conclusions
We conclude that 26 Gy in five daily fractions for breast
radiotherapy is an effective regimen for tumour control.
There is no evidence or scientific rationale to argue against
it for any subgroup. With regards to adverse effects, it is as
well tolerated as moderate hypofractionation over 3 weeks
of daily radiotherapy. Furthermore, it is convenient for pa-
tients and less burdensome for radiotherapy departments.
We recommend that 26 Gy in five daily fractions for all
indications of whole-breast, partial-breast and chest wall
radiotherapy be adopted as the standard of care.Conflicts of Interest
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